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Poster Session-II 115the basis of significant epidermal hyperplasia, dyskeratosis, dermal fi-
brosis with hemorrhage, loss of hair follicles and sebaceious glands,
inflammation of subcutaneous fat tissue and hemorrhagic cysts.
These findings confirmed that GvHD could be induced using the
macaquemodel. The third animal was transplanted with haploident-
ical donor bone marrow (1.1 109 total nucleated cells/kg and 6.9
107 CD31 T cells/kg), but was given T cell costimulation blockade
with abatacept (targeting the CD28/B7 pathway) and an anti-CD40
antibody (targeting the CD40/CD154 pathway) in addition to rapa-
mycin. Abatacept is currently clinically approved for treatment of
rheumatoid arthritis, but has not been added to clinical GvHD reg-
imens, largely due to the paucity of translational efficacy data. This
animal maintained full donor chimerism (including 100% T and B
cell chimerism), until day 63 when he was sacrificed, without signs
of GvHD. Additional animals are now being added to the study, to
confirm these initial results.
Conclusions: 1. We have established a robust non-human pri-
mate model of GvHD using pedigreed and MHC-typed rhesus ma-
caques. 2. We have used this model to begin to test the efficacy of
a novel agent combination, capable of preventing the onset and com-
plications of acute GvHD. 3. Preliminary results suggest that CD28-
and CD40-directed costimulation blockade may be active agents for
the prevention of GvHD. A large scale analysis of their efficacy and
immune consequences is currently underway.320
EVALUATION OF OPTIMAL BLOOD CONCENTRATION OF TACROLIMUS
FOR THE PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONOR
Mori, T., Aisa, Y., Kato, J., Nakamura, Y., Ikeda, Y., Okamoto, S. Keio
University School of Medicine, Tokyo, Japan
Background: Optimal blood concentration of tacrolimus for the
prophylaxis of GVHD after allogeneic hematopoietic stem cell
transplantation (HSCT) has not been established. Our retrospective
analysis has shown that incidence of Grades II-IV acute GVHD in
patients with mean tacrolimus concentration less than 15 ng/ml
was significantly higher than that in patients with mean tacrolimus
concentration 15 ng/ml or higher. The present study has set the tar-
get tacrolimus concentration between 15 and 20 ng/ml, and evalu-
ated the efficacy in preventing the development of acute GVHD
after allogeneic HSCT from unrelated donor.
Patients and Methods: Patients undergoing allogeneic HSCT
from an HLA-serologically matched unrelated donor for hemato-
logical diseases were evaluated. Stem cell source was bone marrow
in all patients. For the prophylaxis of GVHD, tacrolimus and meth-
otrexate were administered. Tacrolimus was given at an initial dose
of 0.03 mg/kg by continuous intravenous infusion from day -1, and
its dose was arranged to maintain its blood level at 15–20ng/ml dur-
ing the first 4 weeks after HSCT.MTXwas given at a dose of 15mg/
m2 on day 1, and 10 mg/m2 on days 3, 6, and 11.
Results: Of the 55 evaluated patients, 20 (36.4%) patients devel-
oped grade II, 2 patients (3.6%) developed grade III, and no patient
developed grade IV acute GVHD. In multivariate analysis, HLA al-
lele mismatch was an only identified risk factor for developing grades
II-IV acute GVHD, while blood concentration of tacrolimus was
not. No serious complications resulting in discontinuation of tacro-
limus were observed.
Conclusions:Tacrolimuscombinedwithmethotrexatecouldeffec-
tively prevent the development of severe acuteGVHD after allogeneic
HSCT from unrelated donor by maintaining its blood concentration
between 15 and 20 ng/ml in the early post-transplant period.321
VISUALIZING THE FATE OF FOXP3 PROTEIN IN HUMAN T-CELLS
Magg, T., Albert, M.H. Dr. von Haunersches Kinderspital der Universi-
taet Muenchen, Munich, Germany
Foxp3 plays a pivotal role in the development and function of reg-
ulatory T cells (Treg) which represent a promising tool for trans-
plantation tolerance induction. In murine but not human T cells,
forced expression of Foxp3 converts naive T cells into functional
Tregs. This might in part be due to the fact that Foxp3 proteinexpression is difficult to track because endogenous Foxp3 is also ex-
pressed in activated human T-cells. We therefore intended to track
the fate of ectopically expressed Foxp3 protein in humanCD41 cells
with the aim of defining why forced Foxp3 overexpression was not
sufficient for gaining regulatory function and to learn about the
physiological regulation of Foxp3 protein in human T cells. We
used a non-viral nucleofection protocol for transfection of human
CD41 cells with a dual-expression plasmid of a GFP-Foxp3 fusion
protein and a truncated low affinity nerve growth factor receptor
(LNGFR) to allow for positive selection of transfected cells. As ex-
pected we could demonstrate that purified, transiently Foxp3 trans-
fected cells only weakly suppressed proliferation of T cells. We
found that the ectopically expressed Foxp3 protein disappeared
more quickly than Foxp3mRNA levels which remained at high levels
for up to 4 days. Also in stably transfected T cell lines GFP-Foxp3
mRNA but not the fusion protein was detectable. We hypothesized
that this might be due to posttranslational protein degradation or
posttranscriptionally decreased protein synthesis. We observed ap-
pearance of Foxp3 protein in stably transfected Jurkat cells treated
with the proteasome inhibitor bortezomib implying ubiquitinylation
as one mechanism of Foxp3 protein degradation. By fluorescent mi-
croscopy we could demonstrate that Foxp3 was relocated from the
nucleus to the cytoplasm within 24 hours after transfection. Using
a plasmid encoding for a Foxp3 protein double-tagged with N-ter-
minal GFP and C-terminal YFP we found that the GFP tagged frag-
ment was relocated to the cytoplasm and disappeared after 4 days,
while the YFP tagged fragment remained in the nucleus. Both a nu-
clear import and a nuclear export motif in the coding sequence of
Foxp3 could be identified. Our findings demonstrate that human
Foxp3 protein expression is subject to a regulatory pathway control-
ling subcellular distribution as well as protein stability. This experi-
mental setup should provide a basis for further conclusions about the
natural biology of this important determinator of Treg function.322
HIGH BAFF:B CELL RATIOS AND CIRCULATING ACTIVATED B CELLS IN
CHRONIC GVHD
Sarantopoulos, S.1, Stevenson, K.E.2, Kim, H.T.2, Cutler, C.S.1,
Bhuiya, N.S.1, Schowalter, M.1, Ho, V.T.1, Joseph, S.J.1, Antin, J.H.1,
Jerome, R.1 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-Farber
Cancer Institute, Boston, MA
Although rituximab is an effective treatment for steroid refractory
chronic GVHD (cGVHD), the mechanisms underlying B cell in-
volvement in cGVHD have not been elucidated. Previous studies
have demonstrated that patients with active cGVHDhave high levels
of BAFF, a pivotal B cell survival cytokine. We hypothesized that B
cell reconstitution in the context of high BAFF after HSCT could
support activated, potentially pathologic B cell populations that are
most dependent on BAFF for survival. We first performed detailed
phenotypic and functional analyses of peripheral B cells in 57 patients
.12 month post-HSCT and 33 healthy controls (see table).
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116 Poster Session-IIPatients with cGVHD had significantly higher BAFF:B cell ratios
and fewer circulating IgD1CD38LoCD27- (naive) and
IgD1CD38HiCD27- (transitional) B cells compared to patients
without cGVHD. All HSCT patient groups had elevated BAFF
levels but patients without cGVHDhad supranormal numbers of na-
ive and transitional B cells resulting in normal BAFF:B cell ratios.
This suggests that increased numbers of naive B cells in patients
without cGVHD reflect a normal B cell homeostatic compensatory
mechanism. Patients with cGVHDhad fewer B cells, but unlike nor-
mal CD271 antigen-experienced B cells, CD271 B cells from
cGVHD patients were in vivo activated and capable of IgG produc-
tion without additional antigen or second signal stimulation. Serial
measurements of BAFF and B cell subsets in a second series of 25 pa-
tients followed for 1 year post-HSCT revealed high BAFF levels as-
sociated with B cell lymphopenia in all patients early post-HSCT.
Following autologous HSCT (n5 8) BAFF levels decreased rapidly
as B cell numbers recovered after transplant. In patients without
cGVHD (n5 8), BAFF levels also decreased as peripheral B cells re-
constituted. In contrast, patients who developed cGVHD (n 5 17)
had persistently elevated BAFF levels. In these patients, elevated
BAFF levels were associated with delayed reconstitution of naive B
cells and proportional increases in antigen-experienced CD271 B
cells in the first year post-HSCT.These studies demonstrate distinct
abnormalities in B cell homeostasis associated with excess BAFF in
patients with cGVHD and begin to delineate mechanisms of B cell
pathophysiology in these patients. BAFF appears to play a critical
role in the maintenance of functionally activated B cells after
HSCT and BAFF targeting agents may be useful in the treatment
of cGVHD.323
FEMALE DONOR H-Y SEROPOSITIVITY DOES NOT PREDICT MALE RECIP-
IENT HCT OUTCOMES, INCLUDING CGVHD
Sahaf, B.1, Narasimhan, B.2, Miller, K.1, Spencer, K.1, Spellman, S.3,
Miklos, D.1 1Stanford University, Stanford, CA; 2Stanford, CA; 3Na-
tional Marrow Donor Program, Minneapolis, MN
Following HLA-identical hematopoietic cell transplantation
(HCT), T and B cells target minor histocompatibility antigens
(mHA) providing beneficial GVL and detrimental GVHD. Males
who have undergone sex-mismatched allogeneic HCT (F/M) ex-
perience more GVHD and less disease relapse compared to any
other donor and recipient gender combination. Y chromosome en-
coded mHA, H-Y antigens, are frequently recognized by T and B
cells following F/MHCT. Earlier, we developed ELISA for 5 H-
Y antigens (DDX3Y, UTY, RPS4Y1, ZFY, and EIF1AY), and
showed 50% of F/M HCT patients develop specific antibodies
for any of these H-Y antigens 4–12 months after HCT. H-Y anti-
body develops in association with cGVHD and persistent disease
remission (p\0.0001). In addition, 30% of females have low-titer
H-Y antibodies, while males have no antibodies. Here, we study
whether preexisting H-Y antibodies in female donors predict
male recipient cGVHD or relapse and overall survival. In collabo-
ration with the NMDP and CIBMTR, pretransplant sera were col-
lected from 289 female donors who donated unrelated bone
marrow for HLA-identical male recipients undergoing myeloabla-
tive HCT for AML(18%), CML(38%), ALL(24%), MDS(13%),
and NHL(7%). Primary immune prophylaxis was CSA/ FK506
plus MTX (78%) and T Cell depletion (22%). With eight year me-
dian follow-up, cGVHD incidence was 47%, 18% relapsed, and
overall survival was 50.2% at one year and 41.8% at two years.
22.3% female donor sera tested positive for any H-Y antigen by
ELISA. To test for alternative antigen presentation chemistry,
H-Y antigens were also printed onto nitrocellulose microarrays at
0.1 mg/ml, incubated with sera and H-Y specific antibody was de-
tected with anti hIgG. H-Y microarrays detected antibodies for
any H-Y antigen in 33% of female donors. H-Y seropositivity
did not correlate with donor age by quartile. H-Y seropositivity
did not correlate with the reported number of donor pregnancies:
nulliparous (38%), one (16%), two (19%), and three or more
(26%). Male recipients of H-Y seropositive donors had 51.2%
cGVHD incidence, 20.1% relapse, and 45.8% overall survival at
2 years. By Cox regression analysis, these clinical outcomes for
seronegative donors did not differ significantly: 42.7% cGVHD,
17.8% relapse, and 39.3% overall survival. Testing for H-Yantibodies in female donors before sex-mismatched HCT will not
predict cGVHD or relapse risk suggesting cGVHD and GVL
responses develop from naı¨ve and not memory lymphocytes.324
NOVEL VACCINATION STRATEGY TO REDUCE ALLOANTIGEN SPECIFIC
RESPONSES
Toubai, T.1, Malter, C.T.1, Tawara, I.2, Sun, Y.1, Lowler, K.P.2,
Ferrara, J.L.M.2, Reddy, P.1 1University of Michigan, Ann Arbor, MI;
2University of Michigan, Ann Arbor, MI
Vaccinations are generally performed to enhance alloantigen spe-
cific immune responses. However, whether it can be utilized to
dampen alloantigen specific immune responses is not known. There-
fore, we tested the hypothesis that vaccination of donors with host-
derived CD8a1 dendritic cells (DCs), which are known to be tolero-
genic, will reduce host-specific donor T cell responses. We vacci-
nated donor (BALB/c) mice with host (B6) bone marrow (BM)
derived CD8a1DCs. Both unvaccinated donors and those vacci-
nated with CD8a- DCs served as controls. BM derived DCs were
sorted for CD11c1CD8a1 or CD11c1CD8a- DCs. CD8a1 and
CD8a- DCs were injected into donors and T cells were harvested.
BALB/c T cells from the B6 CD8a1DC vaccinated mice (hereafter
referred to as CD8a1DC Tvac) demonstrated significantly reduced
proliferation, secretion of IL-2 and IFN-g but greater secretion of
IL-10 in an MLR with B6 DCs when compared with T cells from
non-vaccinated and CD8a- DCs vaccinated mice. By contrast they
demonstrated equivalent proliferation when stimulated with DCs
from a third party (C3HHEJ) demonstrating loss of only antigen
specific responses. The reduction in allo-antigen responses by the
CD8a1DC Tvac cells was also not apparent with T cells from
IL-10 deficient donors, demonstrating a functional relevance for
IL-10. We next evaluated the impact of CD8a1DC Tvac cells in
a clinically relevant model of GVHD. Recipient (B6) mice were le-
thally irradiated and transplanted on day 0 with TCD BM from syn-
geneic (B6) or allogeneic (BALB/c) donors along with 4 106 T cells
from either unvaccinated or B6 BM CD8a1 DC or CD8-DC Tvac
cells from allogeneic (BALB/c) donors. Recipients of CD8a1 DC
Tvac demonstrated significantly better survival (70% vs 0%,
p\0.001) and reduced clinical and histopathological severity of
GVHD when compared with the allogeneic controls. Post-BMT
analyses demonstrated, consistent in vitro, significantly less donor
T cell proliferation, higher serum levels of IL-10 and reduced levels
of TNF-a and IFN-g when compared with the allogeneic controls.
By contrast vaccination of IL-10KO (B6) with BALB/cCD8a1DCs
did not reduce GVHD after B6/BALB/c BMT demonstrating
a critical role for IL-10 in CD8a1DC vaccination mediated protec-
tion. In conclusion, host CD8a1DC vaccination of donors reduces
allo-antigen specific responses in vitro and GVHD severity in vivo.
Thus, vaccination strategies might be employed to reduce undesired
immune responses.325
IMPACT OF CYCLOSPORINE A (CSA) CONCENTRATION ON THE INCI-
DENCE OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Mallard, F., Brissot, E., Chevallier, P., Guillaume, T., Delaunay, J.,
Ayari, S., Saulquin, B., Moreau, P., Harousseau, J.L., Mohty, M.
CHU de Nantes, Nantes, France
Previous studies have demonstrated that the immunosuppressive
effects of CsA (eg. inhibition of calcineurine in lymphocytes) may
be correlated with CsA blood concentration, especially in the con-
text of solid organ transplantation. This report investigated the
impact of CsA concentrations in the early post allo-SCT period,
on the incidence of severe acute GVHD, in 85 consecutive pa-
tients treated in a single centre between Jan. 2006 and Jan.
2008, and for whom CsA concentrations in the blood were mon-
itored weekly. 85 patients received CsA (usually at 3 mg/Kg/d, 2
or 3 d. prior to graft infusion) as a 24-h continuous infusion until
hematopoietic recovery and switch to oral formulation. Dose
modifications of CsA were performed to maintain adequate
trough blood levels and to prevent nephrotoxicity. Median age
